Physician profile
David J Weinerman
NPI 1881883940
$7,815.88
in general payments reported to CMS, 2019-2025
28 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $391 · 2021: $974 · 2022: $1,114 · 2023: $1,038 · 2024: $1,772 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,277 · Education: $34.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,276.69 |
| Education | $34.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,590.17 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Pfizer INC. | $998.68 | 2019-2025 | |
| Janssen Biotech, INC. | $863.15 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $778.88 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $445.99 | 2022-2025 | Dupixent |
| Genzyme Corporation | $438.43 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.73 | 2019-2023 | Trulance |
| Merck Sharp & Dohme LLC | $190.41 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $183.33 | 2021-2023 | |
| Lilly USA, LLC | $164.26 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $145.24 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $129.68 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $108.53 | 2021 | |
| Vivus LLC | $101.00 | 2024-2025 | Qsymia |
| Celltrion USA INC. | $74.41 | 2024-2025 | Vegzelma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.66 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $52.39 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $49.72 | 2019-2021 | |
| Qol Medical, LLC | $34.12 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.97 | 2025 | Voquezna |
| Ardelyx, INC. | $31.23 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $26.27 | 2020 | |
| Novo Nordisk INC | $17.68 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $17.35 | 2023 | Injectafer |
| Laborie Medical Technologies Corp. | $14.63 | 2024 | |
| Boston Scientific Corporation | $14.26 | 2019 | |
| Celgene Corporation | $11.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weinerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.